← Back to Clinical Trials
Recruiting NCT06632743

NCT06632743 Austrian Biobanking Study for Sarcopenia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06632743
Status Recruiting
Phase
Sponsor Medical University of Graz
Condition Sarcopenia
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2023-02-01
Primary Completion 2033-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2023-02-01 with a primary completion date of 2033-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators aim to set up a biobanking study in Graz, Austria, to study sarcopenia in liver cirrhosis and chronic inflammatory bowel disease by collecting a standardized dataset including routine clinical and biochemical tests; biosamples to assess novel biomarker as well as advanced clinical assessments. In a small country like Austria, a nationwide biobanking study can enhance research enormously. The investigators therefore aim to extend the registry to all tertiary liver care centers in Austria in a second step.

Eligibility Criteria

Inclusion Criteria: * Age \>18y * Informed consent * CT/MRI scan as part of routine care within +/-2 month of the study visit Exclusion Criteria: * Hepatic encephalopathy \> grade 2 and or other cognitive disorder not allowing informed consent * Hepatocellular carcinoma stage BCLC C or D * Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol

Contact & Investigator

Central Contact

Vanessa Stadlbauer, MD

✉ vanessa.stadlbauer@medunigraz.at

📞 +43 316 385 82282

Frequently Asked Questions

Who can join the NCT06632743 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06632743 currently recruiting?

Yes, NCT06632743 is actively recruiting participants. Contact the research team at vanessa.stadlbauer@medunigraz.at for enrollment information.

Where is the NCT06632743 trial being conducted?

This trial is being conducted at Graz, Austria.

Who is sponsoring the NCT06632743 clinical trial?

NCT06632743 is sponsored by Medical University of Graz. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology